PLEURAL MALIGNANT MESOTHELIOMA
Clinical trials for PLEURAL MALIGNANT MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new PLEURAL MALIGNANT MESOTHELIOMA trials appear
Sign up with your email to follow new studies for PLEURAL MALIGNANT MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Radiation plus immune therapy: new hope for mesothelioma patients
Disease control OngoingThis early-stage trial is testing whether adding the immunotherapy drug pembrolizumab after radiation therapy is safe for people with a type of lung cancer called malignant pleural mesothelioma. The study involves 24 patients who have not had their lung removed. Researchers want …
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New hope for Tough-to-Treat lung cancer? trial tests adding a Tumor-Starving drug
Disease control OngoingThis study tested if adding a new drug called cediranib to standard chemotherapy (cisplatin and pemetrexed) works better for people with malignant pleural mesothelioma, a serious cancer often linked to asbestos. The trial had two parts: first to find a safe dose of cediranib, the…
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Double attack on deadly cancer: new combo therapy enters trial
Disease control OngoingThis study is testing whether adding a new targeted drug (anetumab ravtansine) to an existing immunotherapy (pembrolizumab) works better than the immunotherapy alone for treating advanced pleural mesothelioma. The trial aims to see if the combination is safe and more effective at…
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC